Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emil Kazounis

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
PLOS Global Public Health|March 24, 2023
Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosisSedona Sweeney, Catherine Berry, Emil Kazounis, et al.
PLOS Global Public Health|April 23, 2025
Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimensDzintars Gotham, Manuel Martin, Melissa J Barber, et al.
Trials|June 13, 2022
TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosisCatherine Berry, Philipp du Cros, Katherine Fielding, et al.
Trials|December 5, 2021
Optimising recruitment to a late-phase tuberculosis clinical trial: a qualitative study exploring patient and practitioner experiences in UzbekistanAlexandra Wharton-Smith, Shona Horter, Emma Douch, et al.
The New England Journal of Medicine|December 22, 2022
A 24-Week, All-Oral Regimen for Rifampin-Resistant TuberculosisBern-Thomas Nyang'wa, Catherine Berry, Emil Kazounis, et al.
The Lancet. Respiratory Medicine|November 19, 2023
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trialBern-Thomas Nyang'wa, Catherine Berry, Emil Kazounis, et al.
Antimicrobial Agents and Chemotherapy|June 6, 2024
How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trialIlaria Motta, Martina Cusinato, Andrew J Ludman, et al.
The Lancet. Global Health|January 31, 2025
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluationSedona Sweeney, Yoko V Laurence, Catherine Berry, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
PLOS Global Public Health|March 24, 2023
Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosisSedona Sweeney, Catherine Berry, Emil Kazounis, et al.
PLOS Global Public Health|April 23, 2025
Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimensDzintars Gotham, Manuel Martin, Melissa J Barber, et al.
Trials|June 13, 2022
TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosisCatherine Berry, Philipp du Cros, Katherine Fielding, et al.
Trials|December 5, 2021
Optimising recruitment to a late-phase tuberculosis clinical trial: a qualitative study exploring patient and practitioner experiences in UzbekistanAlexandra Wharton-Smith, Shona Horter, Emma Douch, et al.
The New England Journal of Medicine|December 22, 2022
A 24-Week, All-Oral Regimen for Rifampin-Resistant TuberculosisBern-Thomas Nyang'wa, Catherine Berry, Emil Kazounis, et al.
The Lancet. Respiratory Medicine|November 19, 2023
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trialBern-Thomas Nyang'wa, Catherine Berry, Emil Kazounis, et al.
Antimicrobial Agents and Chemotherapy|June 6, 2024
How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trialIlaria Motta, Martina Cusinato, Andrew J Ludman, et al.
The Lancet. Global Health|January 31, 2025
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluationSedona Sweeney, Yoko V Laurence, Catherine Berry, et al.
Pageof 1